Biocon Limited has informed the Exchange about approval of Unaudited Condensed Consolidated Interim Financial Statements
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon Limited submitted its unaudited condensed consolidated interim financial statements for H1 FY26 (six months ended Sep 30, 2025) along with the limited review report from B S R & Co. LLP. Consolidated revenue from operations rose to Rs 82,374 million from Rs 70,233 million in H1 FY25, a growth of about 17%. Biosimilars remained the largest segment at Rs 51,471 million (up ~22% YoY), while Generics grew to Rs 13,302 million and CRDMO to Rs 17,601 million. Profit for the period fell sharply to Rs 2,220 million from Rs 8,889 million, mainly because the prior-year period included a one-time gain of Rs 10,573 million from the sale of the Metabolics, Oncology and Critical Care business to Eris Lifesciences. Excluding exceptional items, the underlying profit before tax was Rs 2,973 million versus Rs 11,859 million earlier. Operating cash flow stayed positive at Rs 8,034 million, total equity improved to Rs 3,30,552 million, and total borrowings came down, indicating continued deleveraging.
The sharp drop in headline profit is largely an optical effect of the prior-year one-time business sale gain rather than a real deterioration, so investors should look at underlying operating performance. Strong biosimilars revenue growth and healthy operating cash flow are positives, but weaker margins and continued finance costs suggest margin pressures remain a watchpoint for the stock.